Working… Menu

Safety and Efficacy of the BTL-FR2000 Device for the Treatment of Facial Wrinkles

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03548025
Recruitment Status : Unknown
Verified June 2018 by BTL Industries Ltd..
Recruitment status was:  Recruiting
First Posted : June 6, 2018
Last Update Posted : June 8, 2018
Information provided by (Responsible Party):
BTL Industries Ltd.

Brief Summary:
The study will evaluate safety and effectivity of the BTL-FR2000 device for the treatment of facial wrinkles.

Condition or disease Intervention/treatment Phase
Wrinkle Device: BTL-703 (Treatment group) Not Applicable

Detailed Description:

Subjects will be photographed at the baseline visit. After the treatment phase, subjects will be invited for two follow-up visits - 3 and 6 months after the last therapy. They will be again photographed.

Three blinded evaluators will be scoring the full face photos according to the Fitzpatrick Wrinkle Severity Scale. The improvement of the scores will be evaluated. Every subject will serve as its own control.

In addition, the occurence of an AE during the whole study, as well as the therapy discomfort during the treatment phase, will be followed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of the BTL-FR2000 Device for the Treatment of Facial Wrinkles
Actual Study Start Date : March 1, 2018
Estimated Primary Completion Date : January 1, 2019
Estimated Study Completion Date : March 1, 2019

Arm Intervention/treatment
Experimental: Treatment Group
Treated group of subjects, serves as its own control
Device: BTL-703 (Treatment group)
Treatment with BTL-FR2000 Device

Primary Outcome Measures :
  1. Improvement of facial wrinkles evaluated through the change in the value of the validated scale [ Time Frame: 10 months ]

    Three blinded evaluators will be evaluating the full-face photographs taken at the baseline, last therapy visit and both follow-up visits. They will be evaluating it using the validated Fitzpatrick Wrinkle Severity Scale. According to that scale, subjects are divided in three categories (I, II, III) corresponding to mild, moderate, and severe wrinkling, and degree of elastosis. In addition, a score of 1 to 9 (a linear sliding scale to represent increasing severity of wrinkling) will be given.

    The change in score (value) from the scale before and after the treatment will be calculated.

Secondary Outcome Measures :
  1. Safety - Occurence of AE [ Time Frame: 10 months ]
    The occurence of serious AE during the whole study will be followed.

  2. Safety - Therapy comfort [ Time Frame: 4 months ]
    The discomfort during the therapy will be evaluated immediately after every therapy, using the Discomfort Questionnaire. Subjects will be asked to evaluate the agreement with the statement concerning the conformity of the study treatment. Subjects will be evaluating the agreement by choosing an answer on a scale between 1 (Strongly disagree) and 5 (Strongly agree). Based on a given answers, the therapy comfort will be calculated.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   22 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age ≥ 22 years
  • Voluntarily signed informed consent form

Exclusion Criteria:

  • Bacterial or viral infection, acute inflammations
  • Impaired immune system
  • Isotretinoin in the past 12 months
  • Skin related autoimmune diseases
  • Radiation therapy and chemotherapy
  • Poor healing and unhealed wounds in the treatment area
  • History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin
  • Metal implants
  • Permanent implant in the treated area
  • Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body
  • Facial dermabrasion, facial resurfacing, or deep chemical peeling in the treatment area within 3 months prior to the treatment
  • Current or history of skin cancer, or current condition of any other type of cancer, or pre-malignant moles
  • History of any kind of cancer
  • Active collagen diseases
  • Cardiovascular diseases (such as cardiac and vascular diseases, peripheral arterial disease, thrombophlebitis, thrombosis, etc.)
  • Pregnancy/nursing or IVF procedure
  • History of bleeding coagulopathies, use of anticoagulants
  • Any active condition in the treatment area, such as sores, psoriasis, eczema, rash and rosacea
  • Any surgical procedure in the treatment area within the last three months or before complete healing
  • Poorly controlled endocrine disorders, such as diabetes
  • Children under age of 21
  • Excessively tanned skin from sun, tanning beds or tanning creams within the last two weeks
  • Patients with allergy to anesthetics should not be treated under anesthesia
  • Botox®/collagen/fat injections or other injected bio-material in the treated area within three months prior to treatment
  • Use of non-steroidal anti-inflammatory drugs one week before and after each treatment session
  • Treating over tattoo or permanent makeup

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03548025

Layout table for location contacts
Contact: Georgi Petkov 32 62 22 52 ext +359

Layout table for location information
Aesthe Clinic Recruiting
Sofia, Bulgaria
Contact: Radina Denkova, MD   
Sponsors and Collaborators
BTL Industries Ltd.
Layout table for additonal information
Responsible Party: BTL Industries Ltd. Identifier: NCT03548025    
Other Study ID Numbers: BTL-786-001
First Posted: June 6, 2018    Key Record Dates
Last Update Posted: June 8, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No